1.Long-term survival outcomes and prognostic factors following radical resection of pancreatic body and tail cancer:a retrospective analysis of 992 patients
Dong XU ; Yang WU ; Kai ZHANG ; Nan LYU ; Qianqian WANG ; Pengfei WU ; Jie YIN ; Baobao CAI ; Guodong SHI ; Jianzhen LIN ; Yazhou WANG ; Lingdi YIN ; Zipeng LU ; Min TU ; Jianmin CHEN ; Feng GUO ; Jishu WEI ; Junli WU ; Wentao GAO ; Cuncai DAI ; Yi MIAO ; Kuirong JIANG
Chinese Journal of Surgery 2026;64(1):46-54
Objective:To investigate the survival outcomes and prognostic factors in patients undergoing radical resection for pancreatic body and tail cancer.Methods:A retrospective case series study was conducted on 992 patients who underwent radical resection for pancreatic body and tail cancer at the Pancreatic Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to June 2024. In this study, 577 (58.2%) were male and 415 (41.8%) were female,with an age of (65±9) years (range: 26 to 86 years). Follow-up continued until June 2024. Survival rates were estimated using the Kaplan-Meier method,and prognostic factors were identified using univariate and multivariate Cox proportional hazards models.Results:Among 992 patients,open surgery was the predominant approach (89.1%, 884/992), and radical antegrade modular pancreatosplenectomy (RAMPS) was performed in 317 patients (32.0%). Combined organ resection,venous resection,and arterial resection were performed in 23.5%, 9.3%,and 11.2% of patients,respectively. The rates of R0, R1-1 mm, and R1-direct resections were 49.8% (494/992),41.5% (412/992), and 8.7% (86/992),respectively. Stage ⅡB was the most common TNM stage (32.2%,319/992). A total of 801 patients (80.8%) received adjuvant chemotherapy. The median follow-up period was 32.0(8.8) months(range:3.2 to 105.3 months),during which 508 patients (51.2%) died. The overall median survival (OS) was 26.4 months,with 1-,3-, and 5-year survival rates of 79.0%,40.0%, and 29.0%, respectively. In the recent five years (from 2020 to 2024), the median OS improved significantly to 34.1 months compared to 20.0 months from 2016 to 2019 ( P<0.01). Histological subtype analysis showed that the median OS time was 26.7 months for pancreatic ductal adenocarcinoma (PDAC, n=855),58.9 months for invasive intraductal papillary mucinous carcinoma (IPMC, n=32),and 15.7 months for adenosquamous carcinoma of pancreas (ASCP, n=73) ( P=0.001). Among PDAC patients, adjuvant chemotherapy significantly improved survival (29.1 months vs. 14.4 months, P<0.01);in IPMC patients, adjuvant chemotherapy also extended survival (65.7 months vs. 58.9 months, P=0.047). Although ASCP patients receiving chemotherapy had a longer median OS time than those without (18.8 months vs. 8.9 months),the difference was not statistically significant ( P=0.151). Multivariate Cox regression analysis in PDAC patients indicated that adjuvant chemotherapy, R0 resection, T stage,N stage,and tumor differentiation were independent prognostic factors ( P<0.01). The median OS time by TNM stage was:not reached for stage ⅠA, 51.6 months for ⅠB, 25.5 months for ⅡA, 23.7 months for ⅡB, 23.0 months for Ⅲ, and 14.4 months for Ⅳ. The median OS time for R0,R1-1 mm,and R1-direct resections was 34.1,24.7,and 15.7 months,respectively ( P<0.01). Conclusion:Adjuvant chemotherapy,R0 resection,tumor stage,and differentiation are independent prognostic factors for pancreatic body and tail cancer.
2.Long-term survival outcomes and prognostic factors following radical resection of pancreatic body and tail cancer:a retrospective analysis of 992 patients
Dong XU ; Yang WU ; Kai ZHANG ; Nan LYU ; Qianqian WANG ; Pengfei WU ; Jie YIN ; Baobao CAI ; Guodong SHI ; Jianzhen LIN ; Yazhou WANG ; Lingdi YIN ; Zipeng LU ; Min TU ; Jianmin CHEN ; Feng GUO ; Jishu WEI ; Junli WU ; Wentao GAO ; Cuncai DAI ; Yi MIAO ; Kuirong JIANG
Chinese Journal of Surgery 2026;64(1):46-54
Objective:To investigate the survival outcomes and prognostic factors in patients undergoing radical resection for pancreatic body and tail cancer.Methods:A retrospective case series study was conducted on 992 patients who underwent radical resection for pancreatic body and tail cancer at the Pancreatic Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to June 2024. In this study, 577 (58.2%) were male and 415 (41.8%) were female,with an age of (65±9) years (range: 26 to 86 years). Follow-up continued until June 2024. Survival rates were estimated using the Kaplan-Meier method,and prognostic factors were identified using univariate and multivariate Cox proportional hazards models.Results:Among 992 patients,open surgery was the predominant approach (89.1%, 884/992), and radical antegrade modular pancreatosplenectomy (RAMPS) was performed in 317 patients (32.0%). Combined organ resection,venous resection,and arterial resection were performed in 23.5%, 9.3%,and 11.2% of patients,respectively. The rates of R0, R1-1 mm, and R1-direct resections were 49.8% (494/992),41.5% (412/992), and 8.7% (86/992),respectively. Stage ⅡB was the most common TNM stage (32.2%,319/992). A total of 801 patients (80.8%) received adjuvant chemotherapy. The median follow-up period was 32.0(8.8) months(range:3.2 to 105.3 months),during which 508 patients (51.2%) died. The overall median survival (OS) was 26.4 months,with 1-,3-, and 5-year survival rates of 79.0%,40.0%, and 29.0%, respectively. In the recent five years (from 2020 to 2024), the median OS improved significantly to 34.1 months compared to 20.0 months from 2016 to 2019 ( P<0.01). Histological subtype analysis showed that the median OS time was 26.7 months for pancreatic ductal adenocarcinoma (PDAC, n=855),58.9 months for invasive intraductal papillary mucinous carcinoma (IPMC, n=32),and 15.7 months for adenosquamous carcinoma of pancreas (ASCP, n=73) ( P=0.001). Among PDAC patients, adjuvant chemotherapy significantly improved survival (29.1 months vs. 14.4 months, P<0.01);in IPMC patients, adjuvant chemotherapy also extended survival (65.7 months vs. 58.9 months, P=0.047). Although ASCP patients receiving chemotherapy had a longer median OS time than those without (18.8 months vs. 8.9 months),the difference was not statistically significant ( P=0.151). Multivariate Cox regression analysis in PDAC patients indicated that adjuvant chemotherapy, R0 resection, T stage,N stage,and tumor differentiation were independent prognostic factors ( P<0.01). The median OS time by TNM stage was:not reached for stage ⅠA, 51.6 months for ⅠB, 25.5 months for ⅡA, 23.7 months for ⅡB, 23.0 months for Ⅲ, and 14.4 months for Ⅳ. The median OS time for R0,R1-1 mm,and R1-direct resections was 34.1,24.7,and 15.7 months,respectively ( P<0.01). Conclusion:Adjuvant chemotherapy,R0 resection,tumor stage,and differentiation are independent prognostic factors for pancreatic body and tail cancer.
3.Research Progress of Multidimensional Immunomodulatory Factor ZG16 in Enhancing Antitumor Immune Responses
Longyan NIE ; Xiongchao FANG ; Peng GAO ; Zhuo HAN ; Zhibo FENG ; Tianshuo SONG ; Xiaomeng HAN ; Nan WANG
Cancer Research on Prevention and Treatment 2026;53(9):727-732
The introduction of immunotherapy has changed the traditional paradigms in cancer treatment and has demonstrated substantial clinical benefits across various malignancies. However, this progress is accompanied with emerging challenges, such as immune evasion and low response rates to immunotherapy. As an immunomodulatory molecule, zymogen granule protein 16 (ZG16) plays a crucial role in immunotherapy by inhibiting the binding of programmed death 1 (PD-1) to its ligand PD-L1, preventing immune evasion and restoring the immune system's ability to recognize and eliminate tumor cells. ZG16 is downregulated in multiple gastrointestinal tumors, and its regulatory mechanisms vary depending on the tumor type. ZG16 expression is closely associated with patient prognosis, and it has been identified as a favorable prognostic marker in colorectal cancer. This article provides a systematic overview of the structural characteristics, expression regulation mechanisms, and antitumor immune functions of ZG16.
4.Expression and clinical significance of RAB24 gene in hepatocellular carcinoma based on multi-source databases and clinical cohort validation
Yali GUO ; Yangchen WANG ; Jianhua YANG ; Xiang GAO ; Wenmei MA ; Nan DING ; Qiang HOU ; Wu DAI ; Limei WEN ; Junping HU
Acta Universitatis Medicinalis Anhui 2026;61(9):1647-1656
ObjectiveTo investigate the mRNA expression profile and clinical significance of the RAB24 gene in hepatocellular carcinoma (HCC) based on multi-source database including The Cancer Genome Atlas (TCGA) and clinical cohort validation. MethodsData from TCGA (n=424) were utilized to evaluate the prognostic value of RAB24 expression via Kaplan-Meier analysis and Cox regression models. An independent clinical cohort comprising 90 HCC and 30 paracancerous tissues was established to validate protein expression and histopathological features through immunohistochemistry (IHC) and routine histological staining. The TIMER database was employed to analyze the association between RAB24 and the tumor microenvironment (TME). Furthermore, integrated with LinkedOmics, GSEA and GSVA algorithms were used to quantitatively characterize the core molecular pathways regulated by RAB24. ResultsThe mRNA expression level of RAB24 in HCC was significantly higher than that in non-tumor liver tissues (P<0.05). Kaplan-Meier analysis revealed that the overall survival (OS) of patients in the RAB24 low-expression group was significantly longer compared to the high-expression group (HR=1.570, Log-rank P=0.01). Cox proportional hazards regression analysis demonstrated that RAB24 expression (HR=1.480, P=0.028), T stage (HR=2.949, P<0.001), M stage (HR=4.077, P=0.017), and tumor residual status (HR=2.317, P<0.001) were independent prognostic factors for HCC. RAB24 expression was highly correlated with alpha-fetoprotein (AFP) levels and immune infiltration levels (P<0.01), and showed a significant, low-level positive correlation with the TP53 gene (Rho=0.31, P<0.01). Quantitative analysis of the RAB24 protein in clinical samples validated that RAB24 expression in HCC tissues was significantly elevated compared to non-tumor liver tissues (P<0.05). TIMER analysis confirmed that RAB24 expression was highly associated with the infiltration of multiple immune cells (such as B cells and NK cells), as well as stromal and tumor purity scores in tumor tissues (P<0.01). GSEA/GSVA enrichment revealed that the P53, MYC, and mTORC1 signaling pathways were activated in the RAB24 high-expression group; correlation analysis confirmed that the RAB24 expression level exhibited a significant, low-level positive correlation with the ribosome pathway activity score (r=0.23, P<0.01). ConclusionsThe RAB24 gene, as a poor prognostic factor for HCC patients, is a potential biomarker for HCC diagnosis, treatment and prognosis. The study is expected to lay a theoretical foundation for the precise diagnosis and treatment of clinical HCC.
5.Ditantang Ameliorates MAFLD in Rats Through UDPG-S1P-SREBP Axis-mediated Glycogen Synthesis
Lu PAN ; Zhe ZHAND ; Nan SONG ; Dongyu MIN ; Jiaxin WANG ; Yuanguang DONG ; Yang HONG ; Meiling ZHANG ; Xiaofei SUN ; Jiaru WANG ; Yunfei GAO ; Yupeng PEI
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(22):40-50
ObjectiveTo investigate the effects of Ditantang on metabolic dysfunction-associated fatty liver disease (MAFLD) in rats by focusing on the regulation of glycogen synthesis mediated by the uridine diphosphate glucose (UDPG)-site-1-protease (S1P)-sterol regulatory element-binding protein (SREBP) axis. MethodsMAFLD was modeled in SD rats by feeding a high-fat diet for 12 weeks. Rats were randomized into a control group, a model group, low-, medium-, and high-dose (2.68, 5.36, and 10.72 g·kg-1·d-1, respectively) Ditantang groups, and a positive control (Yishanfu, 0.18 g·kg-1·d-1) group. Starting from week 9 of modeling, each treatment group received corresponding drug interventions via gavage. After the experiment, the serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. The levels of TG, non-esterified fatty acids (NEFA), glycogen, glucose-6-phosphate (G6P), glucose-1-phosphate (G1P), and UDPG in the liver tissue samples were measured by biochemical assay kits. Liver pathological morphology and lipid/glycogen deposition were observed via hematoxylin-eosin (HE) staining, oil red O staining, and Periodic acid-Schiff (PAS) staining. Immunofluorescence assay was conducted to detect the expression and localization of phosphoglucomutase-1 (Pgm1) and UDP-glucose pyrophosphorylase 2 (Ugp2) in the rat liver. Real-time PCR and Western blot were employed to quantify mRNA and protein levels, respectively, of key glycogen synthesis enzymes (Pgm1 and Ugp2), key lipogenesis-related transcription factor SREBP and its target genes [acetyl-CoA carboxylase (ACC), fatty acid synthetase (FASN), and stearoyl-CoA desaturase (SCD1)], as well as S1P. ResultsCompared with the control group, the model group exhibited elevated levels of TC, TG, LDL-C in the serum and TG and NEFA in the liver, decreased serum HDL-C level (P<0.01), reduced hepatic levels of G1P, G6P, UDPG, and glycogen (P<0.01), appearance of fat vacuoles of varying sizes and abundant red lipid droplets, with prominent lipid deposition and reduced areas of deep glycogen staining in the liver tissue, upregulated mRNA and protein levels of SREBP1, S1P, ACC, FASN, and SCD1 (P<0.01), and downregulated mRNA and protein levels of Pgm1 and Ugp2 (P<0.01). Compared with the model group, all doses of Ditantang reduced the levels of TC and TG in the serum and TG and NEFA in the liver, while elevating the serum HDL-C level. Additionally, medium- and high-dose Ditantang reducted the LDL-C level (P<0.05). Ditantang at all doses increased the hepatic levels of G1P, G6P, UDPG, and glycogen, alleviated hepatic steatosis and lipid deposition, enhanced glycogen storage, downregulated the mRNA and protein levels of SREBP1, S1P, ACC, FASN, and SCD1 (P<0.05), while upregulating the expression of Pgm1 and Ugp2 (P<0.01). Immunofluorescence analysis revealed decreased fluorescence intensity of S1P and enhanced fluorescence intensity of Ugp2 (P<0.01). ConclusionDitantang can regulate glycogen synthesis through the UDPG-S1P-SREBP axis to prevent and treat MAFLD.
6.Research progress of nano drug delivery system based on metal-polyphenol network for the diagnosis and treatment of inflammatory diseases
Meng-jie ZHAO ; Xia-li ZHU ; Yi-jing LI ; Zi-ang WANG ; Yun-long ZHAO ; Gao-jian WEI ; Yu CHEN ; Sheng-nan HUANG
Acta Pharmaceutica Sinica 2025;60(2):323-336
Inflammatory diseases (IDs) are a general term of diseases characterized by chronic inflammation as the primary pathogenetic mechanism, which seriously affect the quality of patient′s life and cause significant social and medical burden. Current drugs for IDs include nonsteroidal anti-inflammatory drugs, corticosteroids, immunomodulators, biologics, and antioxidants, but these drugs may cause gastrointestinal side effects, induce or worsen infections, and cause non-response or intolerance. Given the outstanding performance of metal polyphenol network (MPN) in the fields of drug delivery, biomedical imaging, and catalytic therapy, its application in the diagnosis and treatment of IDs has attracted much attention and significant progress has been made. In this paper, we first provide an overview of the types of IDs and their generating mechanisms, then sort out and summarize the different forms of MPN in recent years, and finally discuss in detail the characteristics of MPN and their latest research progress in the diagnosis and treatment of IDs. This research may provide useful references for scientific research and clinical practice in the related fields.
7.Analysis of the detection of respiratory pathogens in children in Zibo area from 2020 to 2022
Renbing ZHAO ; Nan WANG ; Lingyan LI ; Yanhui YANG ; Fangfang GAO ; Mei YANG ; Aixia QI ; Liping CHEN
China Modern Doctor 2025;63(20):35-39
Objective To analyze the distribution characteristics of 13 common respiratory pathogens in children in Zibo area from 2020 to 2022.Methods A total of 3091 hospitalized children with respiratory infections admitted to Zibo Maternal and Child Health Hospital from January 2020 to December 2022 were selected as the subjects.Throat swabs or bronchoalveolar lavage fluid samples were collected from the patients,and 13 common respiratory pathogens were tested to analyze the distribution differences among different genders,ages,and seasons.Results Among 3091 pediatric patients,1794 were found to be infected with pathogens.The top three pathogens were Mycoplasma pneumoniae,rhinovirus,and respiratory syncytial virus(RSV).The single infection rate was 47.75%,while the mixed infection rate was 10.28%,with the most common scenario being a mixed infection of two pathogens.There were statistically significant differences in the pathogen profiles across different age groups(P<0.001):infants had the highest detection rate of RSV,young children were primarily infected with rhinovirus,preschool and school-age children were predominantly infected with Mycoplasma pneumoniae.Seasonal distribution showed that the highest positive rate was in autumn,while the lowest was in spring(P<0.05).In spring,the main pathogens were rhinovirus and Mycoplasma pneumoniae;in summer,they were rhinovirus and parainfluenza virus;in autumn,they were Mycoplasma pneumoniae and RSV;and in winter,the detection rates of Mycoplasma pneumoniae and influenza B virus were higher.Conclusion From 2020 to 2022,Mycoplasma pneumoniae,rhinovirus and RSV were the main pathogens of children's respiratory tract infection in Zibo area,and there were significant differences in the distribution of pathogens among different ages and seasons.
8.Optimization of cellulase-assisted ultrasound extraction process for total flavonoids from Plumbago zeylanica and evaluation of their anti-oxidant activity
Xiao-lu GAO ; Wen-de CHENG ; Yue-yuan WEN ; Shang-ping XING ; Cheng SHI ; Dan ZHU ; Ya-nan XU
Chinese Traditional Patent Medicine 2025;47(11):3580-3585
AIM To optimize the cellulase-assisted ultrasound extraction process for total flavonoids from Plumbago zeylanica L.,and to evaluate their anti-oxidant activity.METHODS With extraction time,liquid-solid ratio,cellulase addition amount,extraction temperature and ultrasonic power as influencing factors,extraction rate of total flavonoids as an evaluation index,the extraction process was optimized by response surface method on the basis of single factor test.Subsequently,The scavenging rates of extract on DPPH,ABTS and OH free radicals were determined.RESULTS The optimal conditions were determined to be 34∶1 for liquid-solid ratio,3%for cellulase addition amount,51 ℃ for extraction temperature,38 min for extraction time,and 400 W for ultrasonic power,the extraction rate of total flavonoids was(33.411±0.97)%.The IC50 values of three free radicals were 0.13,0.042,3.29 mg/mL,respectively.CONCLUSION This reasonable and reliable method can be used for the cellulase-assisted ultrasound extraction of total flavonoids from P.zeylanica with strong anti-oxidant activity.
9.Distribution and drug resistance of multidrug-resistant organisms in newborns in a three-A children's hospital from 2019 to 2023
Hongyan WU ; Chunai ZHANG ; Jun WANG ; Huiping LIU ; Qin WANG ; Ling ZHANG ; Nan GAO ; Xue LI ; Liyuan FU ; Yun YANG ; Yanjie WANG ; Huayu HAN
Chinese Journal of Nosocomiology 2025;35(16):2485-2489
OBJECTIVE To investigate the distribution and drug resistance of multidrug-resistant bacteria in the neonatal intensive care unit of a three-A children's hospital in Henan Province,and to provide reference for ational drug use in clinical practice.METHODS Clinical specimens from hospitalized newborns in neonatal intensive care unit from a three-A children's hospital from Jan.1,2019 to Dec.31,2023 were subjected to etiological exam-ination and drug sensitivity test,and to analyze the distribution and drug resistance of multidrug-resistant bacteri-a in hospitalized newborns.RESULTS During the 5-year period,1139 strains of multidrug-resistant bacteria were i-solated,including 229 gram-positive bacteria(20.11%)and 910 gram-negative bacteria(79.89%).There were 92 strains of methicillin-resistant Staphylococcus aureus(MRSA)(accounting for 8.08%),57 strains(accounting for 5.00%)of methicillin-resistant coagulase-negative Staphylococcus epidermidis and 28 strains(accounting for 2.46%)of methicillin-resistant coagulase-negative human Staphylococcus.370 strains(accounting for 32.48)of carbapenem-resistant Klebsiella pneumoniae(CRKP),268 strains(accounting for 23.53%)of extenspectrum β-lactamase-producing Escherichia coli and 85 strains(accounting for 7.46%)of K.pneumoniae,there were 767 sputum specimens(67.34%),160 blood specimens from peripheral intravenous puncture and central venous cath-eterization(PICC)(14.05%),63 bronchoalveolar lavage fluid specimens(5.53%),29 secretion specimens(eye and wound secretions)(2.54%),and 120 other specimens(10.54%).K.pneumoniae and E.coli producing su-per-broad spectrum β-lactamase,CRKP and MRSA were the main drug-resistant bacteria.CONCLUSION The sit-uation of drug resistance in neonatal intensive care unit is serious,therefore monitoring bacterial resistance should be strengthened according to the clinical laboratory results,and antibiotics should be applied rationally.
10.Prevalence trends of hospital-associated infections and variation of pathogens in a three-A children's hospital from 2020 to 2024
Liping DU ; Fulai ZHANG ; Nan GAO ; Chunai ZHANG ; Liyuan FU
Chinese Journal of Nosocomiology 2025;35(22):3426-3430
OBJECTIVE To understand the surveillance data regarding to prevalence of hospital-associated infections(HAIs)in a three-A children's specialized hospital of Henan Province and analyze the change trends so as to pro-vide bases for developing precise prevention strategies and optimizing the allocation of infection control resources.METHODS The data involving the case information,case-time infection rates,infection sites,distribu-tion of departments and pathogens were collected from the children who were hospitalized in Children's Hospital Affiliated to Zhengzhou University from 2020 to 2024.The statistical analysis was performed by SPSS 25.0 soft-ware.RESULTS A total of 460,516 children who were hospitalized for treatment from 2020 to 2024,3700 of whom had hospital-associated infections,with the incidence of HAIs 0.80%;totally 3907 case-times of children had HAIs,with the case-time infection rate 0.85%.The departments ranking the top 5 incidence rates of HAIs were as follows:hematopoietic stem cell transplantation ward,ward 2 of hemooncology department,ward 1 of hemooncology department,ward of rehabilitation center,neonatal surgery department.The lower respiratory tract was the major infection site,accounting for 41.13%.The children who had respiratory system infections accounted for 65.29%.The gram-negative bacteria were dominant among the pathogens causing the HAIs,accounting for 48.15%;the percentage of viruses showed an upward trend.CONCLUSIONS The incidence of HAIs shows fluctu-ating downward trend.It is necessary to further strengthen the refined management and take targeted infection prevention and control measures for the departments at high risk of HAIs and the high-risk links so as to continu-ously improve the medical quality and safety.

Result Analysis
Print
Save
E-mail